Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clindamycin
Drug ID BADD_D00483
Description Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris.[L11593] It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli.[A190621] Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.[A190657] Clindamycin is derived from, and has largely replaced, [lincomycin], a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from _Streptomyces lincolnensis_ found in a soil sample.[A190621]
Indications and Usage In oral and parenteral formulations, clindamycin is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria, as well as susceptible staphylococci, streptococci, and pneumococci.[L11599,L11602] Used topically, it is indicated for the treatment of acne vulgaris[L11593,L11611,L11605] and is available in combination with [benzoyl peroxide][L11584] or [tretinoin][L11590] for this purpose. Clindamycin is also indicated as a vaginal cream[L11596], suppository[L11608], or gel[L39416] for the treatment of bacterial vaginosis in non-pregnant females. Clindamycin is used for antimicrobial prophylaxis against _Viridans_ group streptococcal infections in susceptible patients undergoing oral, dental, or upper respiratory surgery, and may be used for prophylaxis against bacterial endocarditis in penicillin-allergic patients at high risk of these infections.[L11629]
Marketing Status approved; vet_approved
ATC Code D10AF01; G01AA10; J01FF01
DrugBank ID DB01190
KEGG ID D00277
MeSH ID D002981
PubChem ID 2786
TTD Drug ID D0R0ZL
NDC Product Code 67457-816; 71872-7168; 67457-817; 67457-815; 67457-814; 16781-462
UNII 3U02EL437C
Synonyms Clindamycin | Chlolincocin | 7-Chloro-7-deoxylincomycin | 7 Chloro 7 deoxylincomycin | Chlorlincocin | Dalacin C | Clindamycin Monohydrochloride | Monohydrochloride, Clindamycin | Clindamycin Monohydrochloride, Monohydrate | Monohydrate Clindamycin Monohydrochloride | Monohydrochloride, Monohydrate Clindamycin | Cleocin | Clindamycin Hydrochloride | Hydrochloride, Clindamycin
Chemical Information
Molecular Formula C18H33ClN2O5S
CAS Registry Number 18323-44-9
SMILES CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Peripheral swelling02.05.04.015; 08.01.03.0530.000066%Not Available
Localised oedema14.05.06.009; 08.01.07.011; 02.05.04.006--
General physical health deterioration08.01.03.018--Not Available
Dyschezia07.02.03.005--Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Nodule08.03.05.002--Not Available
Skin burning sensation23.03.03.021; 17.02.06.009--Not Available
Haemorrhage24.07.01.0020.000030%Not Available
Pneumatosis intestinalis07.11.01.0430.000045%Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.003--Not Available
Induration08.01.03.020--Not Available
Hot flush21.02.02.001; 08.01.03.027; 24.03.01.005--
Bacterial infection11.02.01.005--Not Available
Inflammation10.02.01.089; 08.01.05.007--Not Available
Limb discomfort15.03.04.014--Not Available
Sensation of foreign body08.01.09.002--Not Available
Drug intolerance08.06.01.0130.000116%Not Available
Gastrointestinal inflammation07.08.03.007--Not Available
Vulvovaginal mycotic infection21.14.02.004; 11.03.05.004--Not Available
Application site burn23.03.11.013; 12.07.01.038; 08.02.01.038--Not Available
Liver injury12.01.17.012; 09.01.07.0220.000030%Not Available
Cytogenetic abnormality03.20.02.002--Not Available
Vulvovaginal burning sensation21.08.02.007--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Vulvovaginal pain21.08.02.009--
Kounis syndrome10.01.03.037; 02.02.02.020; 24.04.04.0200.000060%Not Available
Acute kidney injury20.01.03.0160.000060%
Bladder dysfunction20.03.03.002--Not Available
Vulvovaginal erythema23.03.06.017; 21.08.02.011--Not Available
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages